LLY

1,085.5

+1.29%↑

JNJ

232.04

+0.69%↑

ABBV

214.86

+1.09%↑

UNH

382.38

+0.69%↑

AZN

186.54

-0.37%↓

LLY

1,085.5

+1.29%↑

JNJ

232.04

+0.69%↑

ABBV

214.86

+1.09%↑

UNH

382.38

+0.69%↑

AZN

186.54

-0.37%↓

LLY

1,085.5

+1.29%↑

JNJ

232.04

+0.69%↑

ABBV

214.86

+1.09%↑

UNH

382.38

+0.69%↑

AZN

186.54

-0.37%↓

LLY

1,085.5

+1.29%↑

JNJ

232.04

+0.69%↑

ABBV

214.86

+1.09%↑

UNH

382.38

+0.69%↑

AZN

186.54

-0.37%↓

LLY

1,085.5

+1.29%↑

JNJ

232.04

+0.69%↑

ABBV

214.86

+1.09%↑

UNH

382.38

+0.69%↑

AZN

186.54

-0.37%↓

Kodu・Aktsiate loetelu・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Avatud

SektorTervishoid

18.48 0.43

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.12

Max

18.76

Põhinäitajad
By Trading Economics
Sissetulek	-607K -51M
Müük	-28M 100M
Aktsiakasum	-0.46
Kasumimarginaal	-51.215
Töötajad	1,784
EBITDA	4.1M -44M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+74.1% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-294M 2.1B
Eelmine avamishind	18.05
Eelmine sulgemishind	18.48

Uudiste sentiment

By Acuity

30%

70%

71 / 344 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. mai 2026, 16:52 UTC

Uudisväärsed sündmused

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26. mai 2026, 23:57 UTC

Tulu

Sociedad Quimica 1Q Rev $1.76B >SQM

26. mai 2026, 23:57 UTC

Tulu

Sociedad Quimica 1Q EPS $1.28 >SQM

26. mai 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26. mai 2026, 21:54 UTC

Tulu

Webco Industries 3Q EPS $11.61 >WEBC

26. mai 2026, 21:54 UTC

Tulu

Webco Industries 3Q Sales $179.6M >WEBC

26. mai 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26. mai 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26. mai 2026, 20:58 UTC

Omandamised, ülevõtmised, äriostud

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26. mai 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26. mai 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26. mai 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26. mai 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26. mai 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26. mai 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26. mai 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26. mai 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26. mai 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26. mai 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26. mai 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

26. mai 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26. mai 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26. mai 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

74.1% tõus

12 kuu keskmine prognoos

Keskmine 32.4 USD 74.1%

Kõrge 44 USD

Madal 21.6 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Zai Lab Ltd ADR aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

71 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.